阿霉素（多柔比星）心肌病
Doxorubicin (adriamycin) cardiomyopathy.
作者信息
Saltiel E, McGuire W
出版信息
West J Med. 1983 Sep;139(3):332-41.
Abstract
Despite its vast utility in clinical oncology, the use of doxorubicin hydrochloride (Adriamycin) is limited by a potentially fatal cardiomyopathy. The following critical review, which examines the natural course, histopathologic effects, risk factors and monitoring indicators of this toxicity, also analyzes recent research of proposed mechanisms, including free radical formation with depletion of detoxifying enzymes, inhibition of vital enzyme systems and alterations in relative calcium concentrations. Prevention of the adverse reaction has been attempted by using such agents as alpha-tocopherol, selenium sulfide, coenzyme Q(10), sulfhydryl donors, nucleosides and razoxane, and via liposomal carriage and alternative methods of administration.
摘要
尽管盐酸多柔比星（阿霉素）在临床肿瘤学中具有广泛用途，但其使用受到潜在致命性心肌病的限制。以下这篇批判性综述，考察了这种毒性的自然病程、组织病理学影响、危险因素和监测指标，还分析了关于其潜在机制的最新研究，包括自由基形成与解毒酶耗竭、重要酶系统抑制以及相对钙浓度改变。已经尝试通过使用α-生育酚、硫化硒、辅酶Q(10)、巯基供体、核苷和雷佐生等药物，以及通过脂质体运载和其他给药方法来预防不良反应。
相似文献
1
Doxorubicin (adriamycin) cardiomyopathy.阿霉素（多柔比星）心肌病
West J Med. 1983 Sep;139(3):332-41.
2
Adriamycin-induced myocardial toxicity: new solutions for an old problem?阿霉素诱导的心肌毒性：老问题的新解决方案？
Int J Cardiol. 2007 Apr 12;117(1):6-15. doi: 10.1016/j.ijcard.2006.05.005. Epub 2006 Jul 24.
3
[Fatal myocardiopathy due to adriamycin in spite of a reportedly non-dangerous cumulative dose].[尽管据报道累积剂量无危险，但阿霉素仍导致致命性心肌病]
Ann Pediatr (Paris). 1989 Feb;36(2):136-40.
4
[Cardiomyopathy due to adriamycin: the possibility of its prevention. Monitoring by noninvasive technics].[阿霉素所致心肌病：预防的可能性。采用非侵入性技术进行监测]
Minerva Med. 1989 Mar;80(3):215-26.
5
Prenylamine inhibition of adriamycin-induced cardiomyopathy in mice.普尼拉明对阿霉素诱导的小鼠心肌病的抑制作用。
Medicina (B Aires). 1982;42(4):409-14.
6
Abrogation of adriamycin-induced cardiotoxicity by selenium in rabbits.硒对阿霉素诱导的家兔心脏毒性的消除作用
Am J Pathol. 1987 Feb;126(2):376-83.
7
8
Adriamycin cardiomyopathy. Fatal outcome of general anaesthesia in a child with adriamycin cardiomyopathy.阿霉素心肌病。一名患有阿霉素心肌病的儿童在全身麻醉下的致命结局。
Anaesthesia. 1988 Apr;43(4):301-4.
9
Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.右丙亚胺和氨磷汀对阿霉素诱导的体内心肌病发展的影响。
Exp Biol Med (Maywood). 2007 Dec;232(11):1414-24. doi: 10.3181/0705-RM-138.
10
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.磷酸二酯酶4型抑制剂对大鼠阿霉素诱导的心肌病的保护作用
J Pharm Pharmacol. 2004 Jun;56(6):757-68. doi: 10.1211/0022357023565.
引用本文的文献
1
The beginning of GPX2 and 30 years later.GPX2 的开端及其 30 年后。
Free Radic Biol Med. 2022 Aug 1;188:419-433. doi: 10.1016/j.freeradbiomed.2022.06.232. Epub 2022 Jul 5.
2
Compound 968 reverses adriamycin resistance in breast cancer MCF-7 cells via inhibiting P-glycoprotein function independently of glutaminase.化合物968通过独立于谷氨酰胺酶抑制P-糖蛋白功能来逆转乳腺癌MCF-7细胞中的阿霉素耐药性。
Cell Death Discov. 2021 Aug 5;7(1):204. doi: 10.1038/s41420-021-00590-1.
3
MicroRNA‑133b alleviates doxorubicin‑induced cardiomyocyte apoptosis and cardiac fibrosis by targeting PTBP1 and TAGLN2.微小 RNA-133b 通过靶向 PTBP1 和 TAGLN2 减轻阿霉素诱导的心肌细胞凋亡和心脏纤维化。
Int J Mol Med. 2021 Jul;48(1). doi: 10.3892/ijmm.2021.4958. Epub 2021 May 13.
4
Recent advances of cocktail chemotherapy by combination drug delivery systems.联合给药系统在鸡尾酒化疗方面的最新进展。
Adv Drug Deliv Rev. 2016 Mar 1;98:19-34. doi: 10.1016/j.addr.2015.10.022. Epub 2015 Nov 6.
5
A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin.流式细胞术克隆形成试验揭示了阿霉素的单细胞效力。
J Pharm Sci. 2015 Dec;104(12):4409-4416. doi: 10.1002/jps.24631. Epub 2015 Sep 7.
6
Clinical Translation of Nanomedicine.纳米医学的临床转化
Chem Rev. 2015 Oct 14;115(19):11147-90. doi: 10.1021/acs.chemrev.5b00116. Epub 2015 Jun 19.
7
Anticancer activity expressed by a library of 2,9-diazaperopyrenium dications.由2,9-二氮杂芘二价阳离子文库所表现出的抗癌活性。
ACS Nano. 2015 Feb 24;9(2):1461-70. doi: 10.1021/nn505895j. Epub 2015 Jan 23.
8
An improved high yield total synthesis and cytotoxicity study of the marine alkaloid neoamphimedine: an ATP-competitive inhibitor of topoisomerase IIα and potent anticancer agent.海洋生物碱新两性霉素的改进型高产率全合成及细胞毒性研究：一种拓扑异构酶IIα的ATP竞争性抑制剂及强效抗癌剂。
Mar Drugs. 2014 Sep 19;12(9):4833-50. doi: 10.3390/md12094833.
9
Nanodiamond-DGEA peptide conjugates for enhanced delivery of doxorubicin to prostate cancer.纳米金刚石-DGEA 肽缀合物用于增强多柔比星向前列腺癌的递送。
Beilstein J Nanotechnol. 2014 Jul 1;5:937-45. doi: 10.3762/bjnano.5.107. eCollection 2014.
10
Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery.水凝胶-纳米粒子复合材料用于光调制癌症治疗药物递送。
J Control Release. 2014 Mar 28;178:63-8. doi: 10.1016/j.jconrel.2014.01.014. Epub 2014 Jan 23.
本文引用的文献
1
Late, late doxorubicin cardiotoxicity.晚期阿霉素心脏毒性
Chest. 1980 Dec;78(6):880-2. doi: 10.1378/chest.78.6.880.
2
Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin.谷胱甘肽和可溶性巯基在阿霉素毒性中的调节作用
J Pharmacol Exp Ther. 1980 Nov;215(2):450-4.
3
Cardiomyopathy in adults after combination adriamycin and DTIC.阿霉素与氮烯咪胺联合应用后成人发生的心肌病
Cancer Treat Rep. 1980 Feb-Mar;64(2-3):353.
4
Evaluation of vitamin E and selenium protection against chronic adriamycin toxicity in rabbits.
Cancer Treat Rep. 1980 Feb-Mar;64(2-3):315-7.
5
Doxorubicin cardiotoxicity in children.
J Pediatr. 1980 Jul;97(1):45-50. doi: 10.1016/s0022-3476(80)80128-4.
6
Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity.
Cancer Treat Rep. 1980 Jan;64(1):47-51.
7
Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit.
Cancer Res. 1980 Jun;40(6):2033-8.
8
Liposomal protection of adriamycin-induced cardiotoxicity in mice.脂质体对阿霉素诱导的小鼠心脏毒性的保护作用。
Cancer Res. 1980 May;40(5):1532-7.
9
Adriamycin cardiotoxicity.
Am Heart J. 1980 May;99(5):671-4. doi: 10.1016/0002-8703(80)90743-7.
Zotero 插件